MARKET

ARDX

ARDX

Ardelyx
NASDAQ
3.120
-0.010
-0.32%
Pre Market: 3.060 -0.06 -1.92% 04:00 11/13 EST
OPEN
3.150
PREV CLOSE
3.130
HIGH
3.165
LOW
3.010
VOLUME
611
TURNOVER
--
52 WEEK HIGH
8.40
52 WEEK LOW
2.800
MARKET CAP
784.28M
P/E (TTM)
-13.8667
1D
5D
1M
3M
1Y
5Y
1D
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
PR Newswire · 17h ago
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDX
PR Newswire · 1d ago
ARDX Deadline: ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
PR Newswire · 2d ago
Ardelyx price target lowered to $11 from $14 at BTIG
TipRanks · 2d ago
Ardelyx: Buy Rating Maintained Despite Price Target Cut to $11 on IBSRELA Growth and Profitability Potential
TipRanks · 2d ago
Ardelyx Price Target Cut to $11.00/Share From $14.00 by BTIG
Dow Jones · 3d ago
Ardelyx Is Maintained at Buy by BTIG
Dow Jones · 3d ago
Weekly Report: what happened at ARDX last week (1102-1106)?
Weekly Report · 3d ago
More
About ARDX
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.